Recent news

Check out the latest news on the field of psychedelics.

Why closing your eyes makes you travel more, says scientific study

By Gabriel García on May 17, 2024

In the ever-evolving field of psychedelic research, a groundbreaking study has recently highlighted the profound impact that closing one’s eyes can have on the intensity of a psychedelic experience. Published in the journal ACS Chemical Neuroscience, the study explores the nuances of “set and setting”, a well-known concept in the psychedelic community that emphasises the importance of mindset and environment during a trip. This study, however, is the first to provide quantitative evidence showing how these factors, particularly eye closure, can modulate the effects of psychedelics such as LSD.

More information

Natural psilocybin more effective in therapy than synthetic psilocybin, new study finds

By Gabriel García on May 8, 2024

Recent research reported by Double Blind Mag has uncovered significant findings that could reshape the landscape of psychedelic-assisted therapy. A study published in the journal Molecular Psychology suggests that a full-spectrum extract of psychedelic mushrooms offers more potent and prolonged therapeutic effects than isolated psilocybin, the main active compound traditionally studied in clinical settings. The study and its implications The research team, comprising experts from institutions such as the Hadassah Medical Center of the Hebrew University of Jerusalem and Boston-based Human Metabolome Technologies, focused on comparing the effects of full-spectrum psychedelic mushroom extract (PME) and chemically synthesised psilocybin (PSIL).

More information

New study says therapeutic use of psilocybin does not cause paranoia

By Gabriel García on April 26, 2024

Marijuana Moment has reported new research from the American Medical Association (AMA) has found that the use of psilocybin in the context of therapy significantly reduces the risk of long-lasting adverse effects. The study, published in JAMA Psychiatry in April, shows that the use of a single dose of psilocybin “is not associated with risk of paranoia”, and other adverse effects, such as headaches, are generally “tolerable and resolve within 48 hours”.

More information

Israel joins research on psychedelics

By Gabriel García on April 14, 2024

In a significant step towards researching the therapeutic effects of psychedelics, Israel has joined the international scene through a pioneering collaboration between Optimi Health Corp. and the Institute for Psychedelic Research at Tel Aviv University (IPR-TLV). This partnership marks Optimi’s foray into the Israeli psychedelic market and promises to contribute to the advancement of knowledge in the field of mental health and addiction. In this collaboration, Optimi will supply MDMA to the IPR-TLV to support research on the effects of this compound in animal models of alcohol addiction.

More information